BioNTech (BNTX), the partner of Pfizer (PFE) for the Comirnaty COVID-19 vaccine, fell 18% in the premarket on Tuesday after its Q4 2025 financials, as its full-year outlook fell short of Street forecasts.
Additionally, BNTX said that its board has initiated an executive search to find successors to founders CEO Ugur Sahin and medical chief Özlem Türeci, who are departing the company by the end of 2026 to manage a newly formed firm focused on mRNA technology.
The German-based company projected €2.0B – €2.3B in revenue for 2026 compared to €2.75B in FactSet consensus, indicating a ~22% YoY decline at the midpoint compared to its last year’s revenue figure of €2.8B.
As for Q4 results, BioNTech (BNTX) reported €907.4M in revenue with a ~24% YoY decline as lower demand for COVID-19 vaccines hurt Comirnaty sales. However, for the full year, the company posted €2.9B in revenue, indicating ~4% YoY growth, mainly due to collaboration revenue from its partner Bristol Myers Squibb (BMY), which boosted its Q3 topline.
BNTX swung to a net loss of €305.0M during Q4 compared to a €259.5M net profit in the prior-year period amid a ~127% YoY growth in other operating expenses, which included charges related to legal settlements.
Looking ahead, the company projected €2.2B – €2.5B in adjusted R&D expenses, indicating a ~16% YoY growth at the midpoint.